Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

V, a member of K-pop sensation BTS, has revealed that he has been dealing with hearing loss in one ear for about two and a half years.

V, whose real name is Kim Tae-hyung, opened up about the condition for the first time during a livestream amid the band's highly anticipated world tour.

"If the hearing in my left ear is at 100, it's only about 30 in my right," V said.

The 30-year-old singer said his hearing became worse while he was serving in the military. However, he initially ignored the problem, believing it was "a matter of mental strength," BBC reported.

He said he is now taking medication and visiting the hospital regularly.

V Reveals Risk Of Stress Fracture

V also admitted to pushing through pain during BTS' current tour, revealing that he is dangerously close to developing a stress fracture in his leg.

“My shin is right at the point just before a stress fracture. Even today on stage, my heart was set on running around, but it hurt too much at points and I couldn’t," he was quoted as saying by Channel News Asia.

Doctors have warned him about inflammation and early bone damage.

“It hasn’t reached a stress fracture yet, but there’s a lot of inflammation in my shin, and I think there’s some microdamage to the bone. I’ll be careful with myself so I can finish this tour properly,” he added.

BTS is currently halfway through its massive Arirang world tour, which will stop in Singapore in December and conclude in the Philippines in March 2027.

What Is Hearing Loss?

Hearing loss can happen when any part of the ear is not working in the usual way. This includes:

• The outer ear
• The middle ear
• The inner ear
• The hearing or acoustic nerve
• The auditory system in the brain

Hearing loss is a growing health concern worldwide. According to the WHO, more than 1.5 billion people—nearly 20% of the world's population—live with some degree of hearing loss. Of these, approximately 430 million people have disabling hearing loss requiring rehabilitation.

Hearing loss can have a significant impact on a person's life, affecting education and job prospects.

What Causes Hearing Loss?

Hearing loss can occur at any time during life. Causes can range from genetic factors to conditions such as Down syndrome or Usher syndrome.

Other factors include:

• Maternal infections during pregnancy
• Complications after birth
• Spending five days or more in a neonatal intensive care unit (NICU)
• Severe jaundice requiring a blood transfusion

How To Prevent Hearing Loss

To help prevent hearing loss in adults:

• Limit exposure to loud noises above 85 decibels.
• Wear ear protection, such as foam plugs or earmuffs, around heavy machinery or at concerts.
• Keep personal headphone use at safe volumes.
• Manage chronic health conditions such as high blood pressure.
• Avoid putting objects such as cotton swabs inside the ears.

Union Health Minister JP Nadda was admitted to AIIMS Delhi after experiencing uneasiness and underwent tests, including a coronary angiography. The hospital, in a statement, said he is stable and under observation in the cardiology department.

JP Nadda Under Observation

The 65-year-old minister was admitted on August 13 after experiencing uneasiness. He underwent tests, including coronary angiography.

“JP Nadda, Minister of Health and Family Welfare, was evaluated for uneasiness with tests including a coronary angiography on the evening of 13th August 2026. He is currently stable and admitted for observation in the Dept of Cardiology,” AIIMS said in a statement.

Is Uneasiness A Sign Of Heart Problems?

Heart problems do not always cause obvious symptoms. While common symptoms include chest pain or pressure, palpitations, and breathing difficulties, reduced blood flow to the heart can sometimes present with subtle signs or no symptoms.

Possible warning signs include:

• Unusual fatigue
• Shortness of breath
• Jaw pain
• Irregular heartbeat
• Swollen feet and ankles
• Dizziness
• Cough
• Leg pain or cramps
• Poor sleep

What Is Coronary Angiography?

Coronary angiography is a test used to check the blood vessels supplying the heart for narrowing or blockages.

A thin catheter is usually inserted through an artery in the wrist or groin. Contrast dye is injected, and X-rays are used to visualize the coronary arteries.

Why Is It Done?

Doctors may recommend coronary angiography for:

• Unexplained chest pain
• Abnormal results from tests such as an ECG, stress test or echocardiogram
• A heart attack, to locate a blocked artery
• Unexplained heart failure or cardiac arrest
• Certain congenital heart conditions

Why Are Heart Checkups Important?

Regular checkups can help detect heart disease early and monitor risk factors such as:

• Blood pressure
• Cholesterol
• Blood sugar

Who Should Consider Regular Heart Checkups?

Regular monitoring can help detect changes early and support timely action to reduce long-term cardiovascular risk.

Regular heart checkups are particularly important for people who:

• Are above 30
• Have a family history of heart disease
• Have high blood pressure, diabetes or high cholesterol
• Smoke or frequently consume alcohol
• Lead a sedentary lifestyle
• Are overweight or obese
• Experience ongoing stress

Common Tests Included In A Heart Checkup

Depending on individual risk factors, a heart checkup may include:

• Blood pressure measurement
• Blood tests for cholesterol, triglycerides and blood sugar
• ECG to assess heart rhythm
• Echocardiography to assess heart structure and function
• TMT or stress test to assess the heart during exertion

Additional tests, such as CT coronary angiography or specialized cardiac biomarkers, may be recommended in some cases.

Sixty-two deaths in Australia have been reported to the medicines regulator, the Therapeutic Goods Administration (TGA), with suspected associations with GLP-1 medicines, including Ozempic, Wegovy and Mounjaro.

The TGA has also received reports of nearly 3,000 serious adverse events involving these medicines, which are used by hundreds of thousands of Australians, The Herald Sun reported.

Reported adverse reactions include nausea, pancreatitis, suicidal thoughts and a rare eye condition that can cause blindness.

62 Death Reports Involving GLP-1 Medicines

Semaglutide, the active ingredient in Ozempic, used for type 2 diabetes, and Wegovy, approved for weight management, had the highest number of reported deaths with suspected associations.

Other medicines with reported suspected associations include Mounjaro (tirzepatide), Saxenda (liraglutide) and Trulicity (dulaglutide). These drugs are approved to treat type 2 diabetes, obesity, or both.

The reported deaths included:

• Semaglutide — 37 reports
• Tirzepatide — 9 reports
• Liraglutide — 11 reports
• Dulaglutide — 5 reports

The TGA states that adverse-event reports alone cannot determine how common a reaction is or be used to directly compare the safety of different medicines. The regulator also said the benefit-risk profile of these medicines remains positive when they are appropriately used for approved indications and in intended patients.

GLP-1 Drugs Carry New Warning For Rare Eye Condition

The TGA recently updated warnings for some GLP-1 medicines concerning non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but serious eye condition.

Product warnings across the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class have been updated because of the potential association with the disorder.

NAION can cause permanent visual impairment, including blindness. The TGA notes that no treatment has been shown to improve visual acuity outcomes in people who develop the condition.

GLP-1 RA medicines are prescription drugs used primarily to manage type 2 diabetes and obesity. Thus, the TGA urged patients not to stop treatment on their own.

“These are prescription medicines, so people taking them should discuss benefits, risks and side effects with their healthcare professional rather than stopping or changing treatment based on headlines alone,” the TGA said.

Death Reports From Other Countries

The Australian reports come amid safety monitoring of GLP-1 medicines in other countries. At the same time, clinical evidence has shown important health benefits from some GLP-1 medicines, including reductions in cardiovascular risk and, in certain populations, overall mortality.

Data submitted to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) showed 82 reported deaths associated with GLP-1 receptor agonists up to January 31, 2025. Of these, 22 were associated with use for weight loss and 60 with use for type 2 diabetes.

In the US, reports in the FDA's FAERS (FDA Adverse Event Reporting System) database have listed 162 deaths associated with Ozempic and Wegovy since 2018.

However, these figures should not be interpreted as confirmed deaths caused by the medicines. Adverse-event reporting systems record suspected associations and cannot by themselves establish a direct causal relationship. Millions of people use GLP-1 medicines, and reported cases can involve other health conditions or factors, including severe complications, dosing errors, and counterfeit or compounded products.